<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300881</url>
  </required_header>
  <id_info>
    <org_study_id>WM562718</org_study_id>
    <nct_id>NCT04300881</nct_id>
  </id_info>
  <brief_title>Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)</brief_title>
  <acronym>TOTEM</acronym>
  <official_title>Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists): The TOTEM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wagner Macula &amp; Retina Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wagner Macula &amp; Retina Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy of eplerenone as an adjunctive treatment to intravitreal ocriplasmin
      for subretinal fluid in comparison to a control group of only receiving intravitreal
      ocriplasmin in patients with symptomatic vitreomacular adhesion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in Central Foveal Thickness (CFT) over time</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Changes as assessed via SD-OCT from the lowest CST measurement in the study, due to disease activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Best Corrected Visual Acuity (BCVA) over time</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Changes as assessed using the visual acuity chart at a starting distance of 4 meters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vitreomacular Traction</condition>
  <condition>Subretinal Edema</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Following intravitreal ocriplasmin therapy</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of age

          -  Symptomatic VMA, VMT, or macular hole

          -  BCVA 20/30 - CF 3' Snellen equivalent

          -  Willing and able to provide signed informed consent and willing to undertake all
             scheduled study-related assessments, visits, and treatments

          -  JETREA® treatment naïve

        Exclusion Criteria:

          -  Patients who are pregnant, planning to become pregnant, or breastfeeding a child

          -  Uncontrolled ocular hypertension or glaucoma in study (defined as IOP ≥ 25mm Hg or a
             cup to disc ratio (CDR) &gt; 0.8 despite treatment with anti-glaucoma medication)

          -  Active malignancies within the last 12 months except appropriately treated carcinoma
             in situ of the crevices, melanoma, and prostate cancers treated with a curative intent

          -  Inability to comply with study or follow-up procedures

          -  Women who may become pregnant or lactating or intend to become pregnant during the
             study

          -  Known drug allergy to ocriplasmin or eplerenone

          -  Patients with known contraindications Eplerenone as outlined in the package insert
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kapil Kapoor, MD</last_name>
    <phone>757-481-4400</phone>
    <email>research@wagnerretina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wagner Macula &amp; Retina Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator, MD</last_name>
      <phone>757-481-4400</phone>
      <email>research@wagnerretina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

